Related Experiment Video
Updated: Dec 1, 2025

Author Spotlight: Advancing the Analysis of Plasma Extracellular Vesicle Proteome for Cardiovascular Biomarker Studies
Published on: January 31, 2025
Role of therapeutic plasma exchanges in systemic vasculitis
Alexis Régent1, Luc Mouthon1, Loïc Guillevin2
1Service de Médecine interne, Centre de Référence Maladies auto-immunes et systémiques rares d'Ile de France, Hôpital Cochin, Assistance Publique Hôpitaux de Paris (AP-HP), 27 rue du Faubourg Saint Jacques, Paris, France; Université de Paris, INSERM U1016, CNRS UMR 8104, LabEx INFLAMEX, F-75014, Paris, France.
Abstract:
Therapeutic management of systemic vasculitides is based on glucocorticoids (GCs), in combination or not with immunosuppressive and/or immunomodulatory agents. Plasma exchange (PLEX) has been used in some vasculitides, with various levels of evidence. Indeed, it is part of the first-line therapy in patients with anti-glomerular basement membrane (GBM) antibodies and in patients with severe hepatitis B related polyarteritis nodosa (PAN). PLEX might also be considered in some selected patients with ANCA-associated vasculitis and cryoglobulinemia vasculitis. Studies support the use of PLEX as second line therapy in refractory Kawasaki disease. Finally, there is not robust data to support the use of PLEX in unselected patients with non-HBV-related PAN or IgA vasculitis. Additional studies are required to address its role in these settings.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Continuous Renal Replacement Therapy
Myocarditis III: Medical Management

